Compass Therapeutics, Inc. (NASDAQ:CMPX) Sees Large Growth in Short Interest

Compass Therapeutics, Inc. (NASDAQ:CMPX) was the recipient of a significant growth in short interest in January. As of January 15th, there was short interest totalling 2,210,000 shares, a growth of 5.2% from the December 31st total of 2,100,000 shares. Approximately 2.6% of the company’s stock are sold short. Based on an average daily volume of 875,000 shares, the short-interest ratio is currently 2.5 days.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Rovin Capital UT ADV acquired a new stake in Compass Therapeutics during the third quarter worth about $25,000. Intech Investment Management LLC acquired a new stake in shares of Compass Therapeutics during the 3rd quarter worth approximately $30,000. XTX Topco Ltd acquired a new stake in shares of Compass Therapeutics during the 3rd quarter worth approximately $37,000. Cubist Systematic Strategies LLC bought a new stake in shares of Compass Therapeutics during the second quarter valued at approximately $41,000. Finally, Bleakley Financial Group LLC raised its stake in shares of Compass Therapeutics by 250.7% in the fourth quarter. Bleakley Financial Group LLC now owns 39,993 shares of the company’s stock valued at $58,000 after purchasing an additional 28,589 shares in the last quarter. Institutional investors and hedge funds own 68.43% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Compass Therapeutics in a report on Wednesday, January 8th. Leerink Partners downgraded Compass Therapeutics from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $5.00 to $4.00 in a research note on Friday, November 15th. Leerink Partnrs cut Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 15th. Finally, D. Boral Capital reissued a “buy” rating and issued a $32.00 price target on shares of Compass Therapeutics in a research report on Wednesday, January 8th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $11.80.

Compass Therapeutics Stock Down 4.3 %

CMPX opened at $3.08 on Tuesday. The stock’s 50 day moving average price is $1.93 and its two-hundred day moving average price is $1.65. The firm has a market capitalization of $423.78 million, a P/E ratio of -8.32 and a beta of 1.15. Compass Therapeutics has a 12-month low of $0.76 and a 12-month high of $3.63.

Compass Therapeutics (NASDAQ:CMPX) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.03. As a group, analysts anticipate that Compass Therapeutics will post -0.35 earnings per share for the current year.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.